The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The roles of STAT6 in regulating B cell fate, activation, and function

(2021) Wei Wang et al.   IMMUNOLOGY LETTERS

JAK-STAT in Early Hematopoiesis and Leukemia

(2021) Eirini Sofia Fasouli et al.   Frontiers in Cell and Developmental Biology

Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia

(2021) Tamer A Othman et al.   Future Oncology

Role of STAT3 signaling pathway in breast cancer

(2020) Jia-hui Ma et al.   Cell Communication and Signaling

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

(2020) Prithviraj Bose et al.   LEUKEMIA

Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers

(2020) Marie Brachet-Botineau et al.   Cancers

JAK–STAT pathway targeting for the treatment of inflammatory bowel disease

(2020) Azucena Salas et al.   Nature Reviews Gastroenterology & Hepatology

Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia

(2020) Theodore P. Braun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

STAT5 is required for lipid breakdown and beta-adrenergic responsiveness of brown adipose tissue

(2020) Doris Kaltenecker et al.   Molecular Metabolism

Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2′-Deoxycytidine Against Pancreatic Cancer

(2020) Rui Kong et al.   Frontiers in Oncology

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

(2020) Moshe Talpaz et al.   LEUKEMIA

The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib

(2020) Anand A. Patel et al.   Current Hematologic Malignancy Reports

Targeting FLT3 mutations in AML: review of current knowledge and evidence

(2019) Naval Daver et al.   LEUKEMIA

Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology

(2019) Carlota Recio et al.   ONCOGENE

C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma

(2019) Jian-Xin Di et al.   ANTI-CANCER DRUGS

Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML

(2019) Jae Yoon Jeon et al.   INVESTIGATIONAL NEW DRUGS

Intersection of Epigenetic and Metabolic Regulation of Histone Modifications in Acute Myeloid Leukemia

(2019) Abhinav Dhall et al.   Frontiers in Oncology

NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia

(2019) Alina Rudorf et al.   BLOOD

Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage

(2019) Silei Bi et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML

(2019) Christina D. Drenberg et al.   Nature Communications

JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia

(2019) Sangeetha Venugopal et al.   BLOOD REVIEWS

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

(2019) Longchuan Bai et al.   CANCER CELL

The potential and controversy of targeting STAT family members in cancer

(2019) Yannick Verhoeven et al.   SEMINARS IN CANCER BIOLOGY

JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation

(2019) Dagmar Gotthardt et al.   Frontiers in Immunology

Incidence, Survival, and Risk Factors for Adults with Acute Myeloid Leukemia Not Otherwise Specified and Acute Myeloid Leukemia with Recurrent Genetic Abnormalities: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database, 2001–2013

(2018) Xiaolu Song et al.   ACTA HAEMATOLOGICA

The regulation of JAKs in cytokine signaling and its breakdown in disease

(2018) Henrik M. Hammarén et al.   CYTOKINE

Pharmacologic inhibition of STAT5 in acute myeloid leukemia

(2018) Bettina Wingelhofer et al.   LEUKEMIA

Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer

(2018) Bettina Wingelhofer et al.   LEUKEMIA

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes

(2018) Mona M. Hosseini et al.   LEUKEMIA

Somatic mutations precede acute myeloid leukemia years before diagnosis

(2018) Pinkal Desai et al.   NATURE MEDICINE

The molecular basis of JAK/STAT inhibition by SOCS1

(2018) Nicholas P. D. Liau et al.   Nature Communications

Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes

(2018) Ilkka S. Junttila   Frontiers in Immunology

Comprehensive genetic diagnosis of acute myeloid leukemia by next generation sequencing

(2018) Elisabeth K.M. Mack et al.   HAEMATOLOGICA

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

(2018) Grzegorz Helbig   MEDICAL ONCOLOGY

Prediction of acute myeloid leukaemia risk in healthy individuals

(2018) Sagi Abelson et al.   NATURE

Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells

(2018) Aditi Shastri et al.   JOURNAL OF CLINICAL INVESTIGATION

Clinical Utility Of A Next-Generation Sequencing Panel For Acute Myeloid Leukemia Diagnostics

(2018) Carmen M. Alonso et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

(2018) Damian Szklarczyk et al.   NUCLEIC ACIDS RESEARCH

Protein Inhibitor of Activated STAT (PIAS) Negatively Regulates the JAK/STAT Pathway by Inhibiting STAT Phosphorylation and Translocation

(2018) Guo-Juan Niu et al.   Frontiers in Immunology

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

(2018) Matthew J. Reilley et al.   Journal for ImmunoTherapy of Cancer

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia

(2017) Karoline V. Gleixner et al.   HAEMATOLOGICA

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

(2017) Ruben A. Mesa et al.   JOURNAL OF CLINICAL ONCOLOGY

Morphologic and Molecular Characteristics of De Novo AML WithJAK2V617F Mutation

(2017) Juliana E. Hidalgo-López et al.   Journal of the National Comprehensive Cancer Network

Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells

(2017) Davide Genini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

STAT5A/5B-specific expansion and transformation of hematopoietic stem cells

(2017) S Ghanem et al.   Blood Cancer Journal

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia

(2017) Karoline V. Gleixner et al.   HAEMATOLOGICA

Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses

(2017) Andrea Majoros et al.   Frontiers in Immunology

The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions

(2017) Ryan Ferrao et al.   Frontiers in Endocrinology

Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia

(2016) Q. Zhang et al.   BLOOD

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

(2016) K. H. Metzeler et al.   BLOOD

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

(2016) Steven Knapper et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers

(2016) W. C. Chen et al.   CANCER RESEARCH

A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells

(2016) Yoshinori Ishikawa et al.   MOLECULAR CANCER THERAPEUTICS

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute myeloid leukemia: advancing clinical trials and promising therapeutics

(2016) Naval Daver et al.   Expert Review of Hematology

‘Acute myeloid leukemia: a comprehensive review and 2016 update’

(2016) I De Kouchkovsky et al.   Blood Cancer Journal

DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders

(2016) Hanae Sato et al.   Frontiers in Oncology

Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

(2015) Michinori Ogura et al.   CANCER SCIENCE

A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

(2015) Naveen Pemmaraju et al.   Clinical Lymphoma Myeloma & Leukemia

Essential role of endocytosis for interleukin-4-receptor-mediated JAK/STAT signalling

(2015) K. Kurgonaite et al.   JOURNAL OF CELL SCIENCE

STAT5A regulates DNMT3A in CD34+/CD38− AML cells

(2015) Asako Takeuchi et al.   LEUKEMIA RESEARCH

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

(2015) David Hong et al.   Science Translational Medicine

Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells

(2014) A. M. Cook et al.   BLOOD

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

(2014) R. C. Lindsley et al.   BLOOD

Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients

(2014) R Kihara et al.   LEUKEMIA

Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase

(2014) Yibing Shan et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Phosphorylated STAT3 physically interacts with NPM and transcriptionally enhances its expression in cancer

(2014) Z Ren et al.   ONCOGENE

Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition

(2014) P. J. Lupardus et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms

(2014) Raajit Rampal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia

(2014) Øystein Bruserud et al.   Expert Review of Hematology

Role of Ubiquitylation in Controlling Suppressor of Cytokine Signalling 3 (SOCS3) Function and Expression

(2014) Jamie Williams et al.   Cells

Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia

(2013) O. Abdel-Wahab et al.   BLOOD

The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges

(2013) A. P. Hutchins et al.   Briefings in Functional Genomics

Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study

(2013) Anjali Shah et al.   BRITISH JOURNAL OF HAEMATOLOGY

Outcome of older patients with acute myeloid leukemia

(2013) Mya S. Thein et al.   CANCER

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia

(2013) M A Dawson et al.   LEUKEMIA

FLT3tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

(2013) Sabine Kayser et al.   LEUKEMIA & LYMPHOMA

SOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibition

(2013) Nadia J Kershaw et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report

(2012) M. S. Redell et al.   BLOOD

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

(2012) A. Eghtedar et al.   BLOOD

The role of STAT5 in lymphocyte development and transformation

(2012) Lynn M Heltemes-Harris et al.   CURRENT OPINION IN IMMUNOLOGY

Age-Related Prognostic Impact of Different Types ofDNMT3AMutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

(2012) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

(2012) Priya Koppikar et al.   NATURE

SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia

(2012) Hanna L.M. Koskela et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor

(2011) M. S. Redell et al.   BLOOD

Transcriptional regulation by STAT6

(2011) Shreevrat Goenka et al.   IMMUNOLOGIC RESEARCH

Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas

(2011) Camilla Pilati et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity

(2011) Brent D. G. Page et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

(2011) S Hart et al.   Blood Cancer Journal

Regulation of hematopoietic cell development and function by Stat3

(2010) Pamela et al.   Frontiers in Bioscience-Landmark

High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V

(2010) Robert Fritsche-Polanz et al.   Molecular Oncology

Alternative Activation of Macrophages: An Immunologic Functional Perspective

(2008) Fernando O. Martinez et al.   Annual Review of Immunology

Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B

(2008) L. Hennighausen et al.   GENES & DEVELOPMENT

Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the ‘second hit’ hypothesis

(2008) H Becker et al.   LEUKEMIA

Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia

(2008) Sampa Ghoshal (Gupta) et al.   LEUKEMIA RESEARCH

Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells

(2008) Angela Colmone et al.   SCIENCE